Chemotherapy Combination Shows Benefits For Prostate Cancer Patients
June 3, 2007
CHICAGO -- Combining an oral dose of Xeloda with a weekly intravenous dose of Docetaxel in patients with metastatic prostate cancer improves patient remission and survival outcomes, according to a phase II clinical trial recently completed at the Barbara Ann Karmanos Cancer Institute in Detroit, MI.
In research presented today at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL, Karmanos physicians found that the combination of the two chemotherapies worked better than Docetaxel alone, which is the current standard of care for metastatic prostate cancer.
"This combination appears extremely effective. We had wheelchair bound patients return to their regular lives. Patients feel so much better and their overall quality of life improves dramatically," said Ulka Vaishampayan, M.D., chair of the genitourinary multidisciplinary team at Karmanos.
On average, patients who undergo the current standard of care see a 45 percent decline in their prostate-specific antigen (PSA) levels. With the combination chemotherapy trial, 73 percent of patients saw at least a 50 percent decrease and nearly a third had a 90 percent decrease.
"We used this combination even in ill patients with severe bone pain and weight loss and saw promising results. This combination is tolerated well, even in elderly patients," stated Dr. Vaishampayan.
Metastatic prostate cancer spreads to the bones more often than other types of metastatic cancers, causing significant pain for patients. Karmanos physicians will continue to follow the 30 patients who enrolled in and completed the trial and work to find other novel agents to combine with Docetaxel.
The lead author for this abstract is Shanthi Marur, M.D., a Karmanos fellow mentored by Dr. Vaishampayan. Dr. Marur received an ASCO merit award for this abstract. ASCO merit awards are given annually to recognize outstanding abstracts submitted for consideration for presentation at an ASCO scientific meeting. The awards are given to oncology fellows in training who are first authors on selected abstracts.
ASCO is the world's leading professional organization representing physicians who treat people with cancer. ASCO's members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.
Based in midtown Detroit, the Barbara Ann Karmanos Cancer Institute is committed to a future free of cancer.